Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 4/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27111331 | 0.79 | LPL (0.33) | LPLLIPGP2RX7FFAR1MAPK1 | |
| SCHEMBL1535070 | 0.76 | LPL (0.41) | LPLLIPGP2RX7FFAR1MAPK1 | |
| SCHEMBL25243329 | 0.75 | PTK2 (0.36) | LPLLIPGP2RX7FFAR1EGFR | |
| SCHEMBL28771993 | 0.74 | LPL (0.35) | LPLLIPGP2RX7FFAR1MAPK1 | |
| SCHEMBL31084022 | 0.73 | LPL (0.53) | LPLLIPGEGFR | |
| SCHEMBL15923768 | 0.72 | EGFR (0.33) | EGFR | |
| SCHEMBL15817447 | 0.72 | EGFR (0.37) | LPLLIPGEGFR | |
| SCHEMBL759177 | 0.71 | LPL (0.41) | LPLLIPGFFAR1EGFR | |
| SCHEMBL3198883 | 0.71 | IDO1 (0.33) | EGFR | |
| SCHEMBL31491330 | 0.70 | CA1 (0.46) | LPLLIPGEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4168407-A1 | BRAF DEGRADERS | C4 Therapeutics, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | LPL 3983/4885LIPG 4468/4885P2RX7 3768/4885 |
| US-20230145336-A1 | BRAF DEGRADERS | BRAF, NRAS, RAF1 | LPL 3840/4885LIPG 4376/4885P2RX7 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.